POTS and the Nervous System

POTS is diagnosed by a heart rate that climbs while the blood pressure holds

The 2019 expert meeting convened by the National Institutes of Health set the rule as a list. A sustained rise of at least 30 beats per minute within 10 minutes of standing. Forty beats between the ages of 12 and 19. Symptoms for at least 3 months, and other explanations excluded. One clause in the middle of that list changes the meaning of all the others.

A young woman stands up from a chair and her heart climbs past 130. The room dims at the edges. Her legs feel heavy and full, her thinking goes soft, and after a few minutes she has to sit down again. The electrocardiogram is normal. The echocardiogram, an ultrasound picture of the heart at work, is normal. The blood work is normal. Somewhere in that sequence the question changes from what is wrong with her to whether anything is.

Symptoms that arrive on standing and ease again on lying down have a name of their own. That name is orthostatic intolerance, and it covers a family of conditions. POTS is the member of that family in which the heart rate climbs steeply and the blood pressure does not fall.

The absence clause is the most important sentence in the POTS criteria

The rise has to happen in the absence of orthostatic hypotension. No sustained drop in the upper pressure number of 20 millimeters of mercury or more. The pressure holds.

In orthostatic hypotension, the more familiar disorder, regulation gives way and the pressure falls. In POTS it is held. The body meets gravity, loses more than 500 milliliters of blood out of its chest within seconds, and still hands a normal number to the cuff. The racing heart is what holding that number costs. The criterion used to diagnose the illness records regulation succeeding at a cost.

The racing heart is the cost. The steady pressure is what the cost bought. The illness is named after the cost.

Broad autonomic failure, where regulation genuinely collapses, belongs to dysautonomia. POTS is the narrower and stranger case. A regulator is still reaching its target, using the one lever it has left. The price is paid in dizziness, in exhaustion, and in years of hearing that the tests came back fine.

What has to be excluded before POTS is the diagnosis

A fast heart on standing is a finding rather than a diagnosis, and the POTS criteria carry an exclusion list long enough to prove it. Anemia, dehydration, an overactive thyroid, fever, infection, several common medications and severe deconditioning all produce the same picture, and most are found with ordinary tests.

Fainting, chest pain and palpitations require medical evaluation. Cardiac causes have to be excluded by a physician before any regulatory explanation is entertained, because some of the rhythms that produce a racing heart are dangerous and treatable. Anyone who loses consciousness, whose heart races at rest, or who has chest pain on exertion needs a doctor rather than a framework.

Each item on the list is a different problem with a different answer. Anemia leaves too few red cells to carry oxygen, so the heart compensates with speed. Dehydration empties the tank. Thyroid hormone drives the rate directly. So does a pheochromocytoma, a rare tumor that releases adrenaline in surges. So do weeks spent in bed.

A structural cause of POTS symptoms is the diagnosis when it is present

Structural, infectious, genetic, endocrine and toxic causes of disease are real. Where one of them is present it is the diagnosis and it is treated as such. A mutation, an infection or a tumor cannot be reduced to poor regulation. Each one still changes how the whole system is organized, and the Unified Model of Tone makes a paired claim about that.

Every disease has a tonal expression, and many are initiated, maintained or amplified by failures of tonal regulation. What the model adds is an account of how a particular body receives a cause, what it does to compensate, and why the same insult runs a different course in two people. The workup comes first and the model begins after it.

One caution comes from the field rather than from the model. The 2015 Heart Rhythm Society consensus statement recommends against sinus node modification in POTS, meaning ablation of the heart's own pacemaker tissue. The rate is an answer to something. Removing the tissue that produces the answer does not remove the question.

Standing moves half a liter of blood out of the chest in seconds

Gravity is always on and blood is heavy. Stand up and more than 500 milliliters of it leaves the chest within seconds, pooling in the soft, easily stretched veins of the abdomen and legs. A heart can only pump what returns to it, and in POTS what returns is short.

The reflex that answers all this is taught in full on dysautonomia. What POTS needs from it is the clock.

Julian Stewart is a pediatrician and physiologist in New York who has spent his career measuring exactly that in young people. Pressure at the brain starts falling about as fast as a person can straighten their knees. In a healthy body it is back inside 30 to 60 seconds, as he sets out in a 2013 review of the orthostatic intolerance syndromes.

Three things keep a person upright while the reflex works. The autonomic nervous system, which tightens vessels and speeds the heart. Enough blood in the tank. And the pumping action of the leg and breathing muscles, which milks blood back toward the chest with every step and every breath. Roughly 4 people in 10 faint at least once in a lifetime. That is how thin the margin is.

Almost all of the work is finished within 30 seconds

A physiology group at the Medical College of Wisconsin assembled the second-by-second sequence in 1994, pulling together every study that had measured any part of the hemodynamic response to upright posture. Arterial pressure and vessel tension dip at 5 to 10 seconds, then rebound and overshoot. Heart rate peaks at 8 to 15 seconds.

Between the fifth and the twentieth minute of standing, the volume of blood in the chest has fallen by roughly a quarter to a third. Cardiac output, meaning the amount of blood the heart moves in a minute, is down by 15 to 30 percent. The heart is running 15 to 30 percent faster than it did lying down. That is a resting person, doing nothing, holding a position.

Five systems have to arrive together, which is what POTS loses

The vessels must tighten at the same moment the heart quickens. The volume must already be adequate before either of them starts. The muscles must pump in time with the breath. And the sensors must be reporting all of it accurately, or the other four are answering the wrong question. Five systems, one event, arriving together. Each of them can be perfectly capable on its own and the answer still fails, because what is being asked for is not five performances. It is one.

Coherence between systems is coupling, and the 30-beat criterion is a measurement of it.

POTS defends its blood pressure target by the most expensive route left

Blood pressure at the brain is not a number the body reports. It is a number the body defends, and the POTS criterion records that the defense is still working.

A defended value has a name in physiology. Homeostasis is the older word for it, and the household image is a thermostat: a target temperature, a sensor, and a furnace that switches on whenever the room drifts below the target. The body runs hundreds of such loops. Temperature, blood sugar, salt concentration, oxygen and pressure at the head are each held inside a window. Each has machinery whose whole job is to bring the value back when it strays.

Peter Sterling showed that the target moves before the demand arrives

The neuroscientist Peter Sterling argued that the thermostat picture is wrong in one important way. A thermostat waits for an error and then corrects it. A body forecasts what it is about to need and moves the value before the demand arrives, which is why blood pressure begins to climb before a person has finished standing.

He called this allostasis, stability achieved through change, in a 2012 paper. The claim that matters for POTS is the second half of his argument. Holding a value against pressure costs something real, and the organism pays it.

That is what the diagnostic criterion is describing. The pressure does not fall, which means the target has not been abandoned. What has been lost is the cheap way of reaching it. A person whose leg vessels tighten properly holds pressure with a modest rise in heart rate. A person whose leg vessels do not tighten holds the same pressure by beating faster, and keeps paying for it every minute they stay upright. The target is met either way. Only the bill is different.

The value a system defends is its set point, and the accumulated cost of defending it is load. Which is why a normal blood pressure reading in a POTS patient is a finding rather than a reassurance. Somebody is paying for that number.

The sensor that reports pressure to the brainstem measures stretch instead

For more than 80 years physiologists knew that something in the wall of a large artery reports pressure to the brainstem, and nobody knew what molecule did the sensing. The answer, found in 2018, also explains how that report can be wrong in POTS.

A team of molecular neuroscientists at Scripps led by Ardem Patapoutian, working with the cardiovascular physiologists Mark Chapleau and Francois Abboud in Iowa and the sensory biologist Stephen Liberles at Harvard, went looking for it. They deleted two mechanically activated ion channels from the sensory nerve cells of mice. The channels, PIEZO1 and PIEZO2, are pores that open when the membrane holding them is physically pulled.

Without them the reflex vanished, and the animals' blood pressure swung wildly, exactly as it does when baroreceptor nerves are cut. Switching the PIEZO2 cells back on with light fired the reflex on command, which the team reported as evidence that PIEZOs mediate neuronal sensing of blood pressure. Patapoutian shared the 2021 Nobel Prize in Physiology or Medicine for the discovery of these channels.

A pore that opens when it is pulled can only measure stretch

The nerve endings carrying those channels are woven into the wall of the aorta, and into the small swelling where each carotid artery divides in the neck. They are called baroreceptors, which translates as pressure receivers, and the name is wrong in a way that matters for POTS. A vessel with more blood in it is a vessel under more tension, and tension is what deforms the ending. More stretch, faster firing. Less stretch, slower firing.

What the brainstem does with that firing rate inside a single heartbeat is the arterial baroreflex, and its full anatomy belongs to dysautonomia. The short version carries POTS. The reflex eases the vagal brake that holds the heart back, presses the sympathetic accelerator that speeds the heart and tightens the vessels, and it is the fastest regulator the circulation owns.

Here is what that means for a person who cannot stand up. The brain has no direct access to its own blood pressure. It has a report about a wall, delivered as a firing rate, from sensors embedded in tissue whose stiffness can change. The fidelity of that report is input quality, and in POTS it ends up carrying more weight than the heart rate does. Everything the brainstem does next is done to the report rather than to the world.

The 30-beat POTS threshold is a committee line rather than a natural boundary

Two studies show how much give that line has. Among healthy children aged 8 to 19, 42 percent clear 30 beats on tilt. In the same patients on the same afternoon, tilt testing and standing differ by up to 13 beats.

The name came first. In 1993 Ronald Schondorf was a neurologist at McGill in Montreal, working with the autonomic laboratory at the Mayo Clinic. He went back through the records of every patient aged 20 to 51 who had passed through that laboratory with a racing heart at rest or on tilting. He was testing a specific idea, that these people had a mild version of a known nerve injury, the whole-body autonomic failure that usually arrives suddenly and severely.

What he described is the picture the field still uses. The patients were mostly women. The illness had begun suddenly, with relentless lightheadedness, exhaustion, or a gut that had stopped moving properly. In 7 of them a viral illness appeared to have come first. Sweat testing was abnormal in some. Sweat glands are driven by small sympathetic nerves, so provoking a patch of skin chemically and measuring what it produces reads those nerves directly.

An abnormal sweat response is direct evidence of nerve damage. In some patients the catecholamines also rose too far on standing. Catecholamines are the family of stress chemicals that includes adrenaline and noradrenaline, and noradrenaline is the same molecule that American papers call norepinephrine. He concluded in print that this was an attenuated form of acute pandysautonomia, and the paper put the name into circulation.

Three consensus documents fixed the POTS definition

In 2011 twenty-seven autonomic specialists from Europe and North America fixed the definitions in a single consensus statement. Among them were the neurologists Roy Freeman, Phillip Low and Eduardo Benarroch. The internist Wouter Wieling signed it, as did the clinical pharmacologists Italo Biaggioni and David Robertson, the physicians Giris Jacob and Christopher Mathias, and the cardiologist Satish Raj. Their statement set the 30-beat rule, the 10-minute window and the absence clause.

In 2015 the Heart Rhythm Society convened 20 cardiologists and autonomic specialists, including Robert Sheldon, Blair Grubb and Win-Kuang Shen, to grade the evidence behind every treatment then in use. That document is where the caution against ablation comes from. The 2019 meeting at the National Institutes of Health brought 30 investigators together, added the 3-month duration to the criteria, and stated plainly that no medication is approved specifically for POTS.

The second half of that 2019 document is a list of what nobody knows. The mechanisms are unresolved. The proposed subtypes have never been validated. There is no biomarker. The trials are small. The diagnostic delay is unacceptable. Those gaps are data. A field that lists them in its own consensus statement has said where the mechanism is still unknown.

Nearly half of healthy adolescents clear the adult POTS line

Wolfgang Singer, a neurologist at the Mayo Clinic, asked whether the adult rule means anything in a teenager, since the heart rate response to standing changes as a child grows. He tilted 106 healthy children aged 8 to 19 and compared them with 654 young patients referred for orthostatic symptoms, asking what postural tachycardia in children actually is.

Forty-two percent of the perfectly healthy children cleared 30 beats. The ninety-fifth percentile among them was about 43 beats. Applied to adolescents, the adult criterion labels nearly half of normal children abnormal, which is why the threshold for young people was raised to 40.

The instrument changes the POTS number by 13 beats

The Vanderbilt autonomic group, with Walker Plash as first author, put the same 15 patients and 15 controls through both of the tests in common use, comparing tilt testing against standing hemodynamics. One test is a tilt table: a padded table with a footboard, onto which the patient is strapped before the whole table is rotated toward vertical.

The other is standing on your own feet for the same 30 minutes. Tilting produced a larger rise at every 5-minute mark. At 5 minutes the gap was 38 beats against 33. At 30 minutes it was 51 against 38.

The reason is the leg muscles. Strapped to a tilting table a person cannot use the pump that normally milks blood back toward the chest, so the circulation must hold pressure with rate and vessel tone alone. That is the harder test, and the same body on the same afternoon can differ by 13 beats depending on which one it is given.

Thirteen beats is most of the distance between meeting the criterion and not meeting it. The same data make it sharper still. At 30 minutes of tilt, the 30-beat rule flagged 4 healthy controls in 5 as abnormal.

Two other tools belong here. Phillip Low built the composite autonomic scoring scale in 1993 so that separate autonomic tests could be combined into one number corrected for age and sex. It scores sweating, the beat-to-beat change in heart rate during slow breathing, the pressure response to a forced exhalation against resistance, and the response to tilt. And blood volume can be measured directly rather than estimated, by tagging albumin with a tracer and letting it distribute through the circulation.

This is what happens when a continuous regulatory variable is cut with a line for administrative purposes. The 30-beat threshold is a convention, and the question it leaves is what the convention is about.

POTS patients are 94 percent women, and wait a median 2 years for the diagnosis

Researchers in Calgary and Nashville assembled the largest sample of these patients ever collected. Working with a patient organization, they surveyed 4,835 people with a physician-confirmed diagnosis. The authors included Kate Bourne and Satish Raj in Calgary, and Lauren Stiles, who works in neurology at Stony Brook and at the patient organization Dysautonomia International.

Ninety-four percent were women. About half had become ill in adolescence, and 14 was the single most common age of onset. The median wait from first symptom to diagnosis was 24 months, and the middle half of the sample waited between 6 months and 6 years, according to that community survey. Nearly everyone reported lightheadedness, a racing heart, near-fainting, headache and trouble concentrating.

What POTS costs a working life

The same collaboration asked 5,556 adults what the illness had cost them and found significant employment and economic loss. Seventy percent had lost income, and two-thirds of those still working said they would work more hours if the illness allowed. Ninety-five percent were paying out of pocket for care.

Earlier, in 2002, the health psychologist Lisa Benrud-Larson measured quality of life in POTS at the Mayo autonomic laboratory. She used the standard questionnaire applied across all of medicine, so that the scores could be set beside other diseases and read directly. Physical functioning and role limitation landed in the territory of serious chronic organ disease.

Both surveys recruited through a patient advocacy organization, which means the samples selected themselves and cannot estimate how common the illness is in the population. The demographics and the delay repeat across every referral series in this literature. A decade of Mayo Clinic records covers 152 patients, 87 percent of them women, average age 30, ill for 4 years before assessment.

A young woman with a normal electrocardiogram, a fast pulse and a story about feeling terrible on standing is one of the easiest patients in medicine to disbelieve. That is a fact about diagnostic culture rather than about POTS, and 2 years of disbelief is one of the measurable harms.

The experiment that separated the POTS heart rate from the fear of it

Shizue Masuki and Michael Joyner, both physiologists at the Mayo Clinic, built an apparatus that produces the POTS tachycardia without the person moving, and then removed one variable at a time. The tachycardia followed the blood and not the fear.

Fourteen patients and 10 controls lay inside a sealed box that seals at the waist and lowers the air pressure around the legs. That drags blood downward exactly as standing does, while the person stays flat and still. Heart rates rose 39 beats per minute in the patients against 19 in the controls. Then the researchers inflated pressure trousers around the legs to stop the pooling while the suction continued, so the experience was unchanged and only the blood shift was blocked.

The rise collapsed to 9 beats. Then they ran the vacuum pump with no suction at all, so the noise and the sensation were identical and nothing moved. There was no rise whatsoever. Then they gave both groups mental arithmetic, a pure psychological stressor. Heart rate rose by the same amount in both, 18 beats against 19, which is why they titled the paper a demonstration that the excessive heart rate response is not caused by anxiety.

Both halves of that study deserve reporting. The patients did score higher than controls on anxiety, on a scale of how closely a person attends to sensations from inside the body, and on catastrophic thinking. Those scores predicted nothing. They did not track the heart rate response to the suction and they did not track the response to the arithmetic.

Formal psychiatric assessment finds inattention rather than an anxiety disorder

A psychiatrist at Vanderbilt took the accusation seriously in a different way, giving 21 patients structured psychiatric interviews and comparing them with people diagnosed with attention deficit hyperactivity disorder and with healthy controls. Here too the picture has two halves. The patients had mild depression and scored as moderately anxious on a standard anxiety inventory. What they did not have was any excess of lifetime depression or anxiety disorders compared with the general population.

Anxiety sensitivity, the fear of one's own bodily alarm signals, was normal too. What they did have was measurable inattention well above controls, absent in childhood, reported in a 2009 study of psychiatric profile and attention deficits. POTS patients look anxious without carrying an anxiety disorder, and the brain fog they keep describing is real enough to score on a test.

A racing heart is evidence a brain is entitled to build fear on

The autonomic neurologists Andrew Owens and Christopher Mathias, working with the neuropsychiatrist Hugo Critchley, have argued that the arrow usually points the other way in disorders of autonomic overexcitation. A racing heart and a surge of adrenaline are the body's own evidence that something is wrong, and a brain builds fear on top of evidence, because that is what evidence is for.

The neuroanatomist Bud Craig, tracing the small nerve fibers that carry news from inside the body, proposed in 2002 that they form a single sense of the body's physiological condition. Their route runs to the insular cortex, a region folded deep in the brain that assembles the body's internal condition into one picture. On that account thirst, breathlessness and a pounding chest are readings taken off a map. A body that keeps filing an emergency report will eventually be experienced as an emergency.

Being disbelieved for years is its own injury, and it lands on people who are already exhausted. If you are thinking about harming yourself, contact emergency services or the 988 Suicide and Crisis Lifeline.

Four POTS patterns that show up together in the same patient

The literature describes four patterns: neuropathic, hyperadrenergic, hypovolemic and deconditioned. The Vanderbilt review by Emily Garland and Satish Raj states directly that patients commonly show features of more than one. The 2019 National Institutes of Health consensus agrees, and adds that the subtypes have never been validated as stable groups.

The four are measurable in the same person, in different proportions, on different days. Two of them turn on the synapse, which is the microscopic gap where one nerve passes its signal to the next by releasing a chemical into it.

The measurements behind these four labels are more interesting than the labels. In every case what was found is a system compensating rather than a system failing.

The POTS patients with visible nerve loss were the milder ones

Five laboratories measured the sympathetic nerves of POTS patients by five different methods, and the results converge on one description. The system is working harder with fewer instruments.

The legs stop answering

A team at the Vanderbilt autonomic center, led by the physician Giris Jacob with the clinical pharmacologist David Robertson, suspected that in some patients the sympathetic nerves supplying the legs had partly died. They tested it with a technique worth understanding. When a sympathetic nerve fires, some of the noradrenaline it releases leaks into the vein draining that tissue, so the concentration in that vein measures how hard the local nerves are working.

They sampled arm and leg veins in 10 patients and 8 matched controls, at rest and after three separate provocations, and published the result as the neuropathic postural tachycardia syndrome. At rest the femoral vein concentration was already lower in the patients, 135 picograms per milliliter against 215. Challenged, the arms of both groups responded normally. The legs of the patients barely responded at all.

The fibers can be counted, and fewer fibers meant milder POTS

The neurologists Christopher Gibbons and Roy Freeman at Harvard took skin biopsies from 24 patients and 10 controls and counted the tiny nerve fibers running up into the epidermis, the outer layer of the skin. Nine of the 24 had genuinely reduced fiber density along with abnormal small-fiber and sweat function, reported as structural and functional small fiber abnormalities. The result ran the other way.

Those 9 had lower heart rates lying and tilted, a weaker parasympathetic brake, less anxiety and depression, and better quality of life than the patients whose nerves looked normal. Visible nerve loss went with a milder illness. In this sample 15 of the 24 had no demonstrable neuropathy at all, while the larger Mayo series put the neuropathic share at about half. Both readings can sit side by side.

The transmitter is not cleared

In 2000 a team at Vanderbilt studied one severely affected patient and found a single point mutation crippling the norepinephrine transporter. That protein vacuums noradrenaline back out of the synapse once the signal has been delivered. The chemical lingered in the gap, so an ordinary burst of sympathetic traffic acted like a much bigger one.

The same mutation turned up in a relative, in what they described as orthostatic intolerance associated with norepinephrine-transporter deficiency. It is rare and it does not explain POTS in general. What it demonstrates cleanly is that this can be a clearance problem rather than an overproduction problem.

Three instruments, one patient group

The cardiovascular neuroscientists Elisabeth Lambert and Murray Esler at the Baker Institute in Melbourne combined three techniques in the same people. A microelectrode pushed through the skin into a leg nerve, which lets you listen to sympathetic bursts as they happen. A radiotracer method that measures how much noradrenaline spills into the whole circulation. And a laboratory assay on a small forearm vein biopsy, which measures how much of one specific protein a tissue holds.

On tilting, nerve traffic rose more than twice as steeply in the patients. Total spillover into the blood rose by the same proportion in both groups. Transporter protein in the patients' own nerves was reduced, which they reported in 2008 as altered sympathetic reactivity with reduced transporter expression. More firing, less clearance, and no more total output.

The system pushes harder for less

The neurologists Istvan Bonyhay and Roy Freeman put the microelectrode into a nerve behind the knee, in 9 patients and 9 controls. Then they dropped blood pressure with a drug, to see how hard each system would work to defend it. At rest the number of bursts per minute matched controls, though per heartbeat the patients fired less often.

When pressure fell, the patients produced far more traffic than controls for the same drop, as they reported in a 2004 study of sympathetic activity during hypotensive stress. What did not increase was the size of each burst, which reflects how many fibers are firing together. That is the signature you would expect if some of the fibers were gone.

More traffic, smaller bursts, less transporter protein, fewer fibers. The system was working harder with fewer instruments.

In POTS the kidney behaves as though the tank were full

Satish Raj measured blood volume directly in 15 patients and 14 controls and found them genuinely short, by about 334 milliliters of plasma and 689 milliliters of total blood volume. Renin sat at exactly the control value and aldosterone at about half of it.

The kidney defends blood volume with two hormones. Renin is the enzyme it releases when flow or salt delivery drops, and it starts a cascade that tightens vessels. Aldosterone sits at the end of that cascade and tells the kidney to hold on to salt and the water that follows it. Low volume should raise both. That hormone machinery gets its fuller teaching on long COVID. What POTS needs is the arithmetic.

Raj worked with Italo Biaggioni and David Robertson at Vanderbilt, using albumin tagged with a tracer rather than an estimate, and measuring both hormones at the same time. Aldosterone came in at 190 against 380 picomoles per liter, and they named the result a renin-aldosterone paradox with perturbed blood volume regulation. The tank was low and the kidney was behaving as though it were full.

There was a red cell deficit too, about 356 milliliters in the patients against 218 in the controls. Red cell volume is governed by erythropoietin, another kidney hormone, which tells the marrow how many red cells to make. Nobody measured erythropoietin here, so that second signal is inference and not data. It is why they concluded that the kidney may be central to POTS.

That is a reporting failure rather than a pump failure. Somewhere between the sensors that read volume and the organ that defends it, the message about how full the system is has been distorted.

The POTS heart is smaller and every beat carries less

Qi Fu is an exercise physiologist in Dallas. Benjamin Levine is a cardiologist who had spent a career studying what bed rest and spaceflight do to hearts. They put 27 patients through autonomic testing, cardiac magnetic resonance imaging and direct blood volume measurement.

Their 2010 account of the cardiac origins of POTS put mass of the left ventricle about 13 percent below controls. That chamber pumps blood out to the body, and blood volume ran about 15 percent lower. Baroreflex function on standard autonomic testing was no different from healthy people.

Stroke volume is the amount of blood the heart ejects in one contraction. Multiply it by the rate and you have cardiac output, which is why a small stroke volume forces a fast heart. Thirteen patients and 10 controls cycled at graded workloads both lying down and sitting up, with the physiologists John Eisenach and Shizue Masuki measuring stroke volume during exercise throughout.

Lying down the stroke volumes were close, though the patients' hearts were already beating faster, 76 against 62. Upright the gap opened. The patients moved 57 milliliters per beat at rest against 81 in controls, and 70 against 94 at the hardest workload. How far a person's stroke volume fell predicted how fast their heart ran. The tachycardia was arithmetic.

What a decade of POTS records shows

The neurologists Mark Thieben, Paola Sandroni and Phillip Low reviewed 10 years at one of the world's busiest autonomic laboratories. One hundred and fifty-two patients, every one with a full reflex screen, in the Mayo Clinic experience of POTS. The mean heart rate rise was 44 beats.

Half had abnormal sweating on two separate tests, and about a third had impaired blood pressure responses on the same battery, so at least half fitted a neuropathic pattern. Onset was subacute in 14 percent. Twenty-nine percent looked hyperadrenergic and a similar proportion looked volume-depleted.

They drew their own conclusion in 2007, and it is the one the model would have argued for. The hyperadrenergic and hypovolemic findings, they wrote, are probably compensatory or aggravating rather than causal. A model organized around compensation starts from there rather than arriving at it.

Deconditioning explains part of POTS and leaves the rest standing

Ninety percent of 184 patients referred for orthostatic intolerance had a maximum oxygen uptake below 85 percent of predicted, which is the accepted definition of deconditioning. That study is a single snapshot, and it cannot say what came first.

Michael Joyner and Shizue Masuki built the Mayo suction chamber. They laid the POTS findings beside the findings from bed rest and spaceflight and asked whether the two are the same or different. Small heart, low blood volume, high standing heart rate, poor exercise tolerance. The lists match almost item for item. Their argument was never that patients are lazy. It was that the field had not shown a physiological signature which disuse could not produce.

The largest fitness study in POTS is uncomfortable reading

A Mayo group reviewed 184 patients referred for orthostatic intolerance who had undergone both autonomic and formal exercise testing. The neurologist Ajay Parsaik was first author, working with the exercise physiologist Thomas Allison and the neurologists Wolfgang Singer, Paola Sandroni and Eduardo Benarroch. Eighty-four of the patients met the tachycardia criterion and 100 did not.

Maximum oxygen uptake is the ceiling on how much oxygen a person can use during hard exercise, and it is the standard measure of fitness. Their report on deconditioning in patients with orthostatic intolerance put 95 percent of those who met the criterion and 91 percent of those who did not below the deconditioning threshold. It was unrelated to age, sex or illness duration, and no autonomic measurement predicted who was deconditioned.

The counterweight is equally real. That study is cross-sectional, a single snapshot, so it cannot say whether the deconditioning came before the illness or after it. Many of these patients were fit and became ill abruptly after an infection. Deconditioning also fails to explain the partly denervated legs, the reduced transporter protein, or a kidney that will not defend its own volume.

Disuse genuinely does degrade the reflex, as the space program showed

A NASA-funded physiology team wanted to know why astronauts faint on returning to gravity. They put 11 healthy men in bed at a 6-degree head-down tilt for 30 days, which is the standard ground model of weightlessness. They tested the baroreflex directly with a collar around the neck. The collar applies suction and pressure, fooling the carotid stretch sensors into reporting a pressure that is not there, and how much the heart slows in answer is the measure.

The reflex went blunt by day 12 and was still blunt 5 days after the men got up, in a 1990 report that head-down bed rest impairs vagal baroreflex responses. The 4 who fainted on standing had lost far more of the reflex response than the 6 who did not. Plasma volume fell about 15 percent, and that fall bore no relation to the change in the reflex.

Read through the model, the dispute stops being a fight over which side is right. An input never acts on an empty body. Rest arrives at a nervous system that already has a history, and what it does there depends on that history.

A body that stopped moving because it could not stand, and a body that cannot stand because it stopped moving, will look identical in a cross-section and will need different things. The question is not which comes first in general. It is which came first in this person, and the field has not built the study that answers it. Time course is the axis that argument lives on.

Antibodies that make POTS vessels ask for more signal

Serum from all 14 patients in one Oklahoma study narrowed living arterioles to 69 percent of their starting width, against 91 percent for control serum. The same serum shifted the vessel's dose-response curve to the right. A 2022 study using the commercial assay found no difference between 116 patients and 81 controls. Both results are informative.

The idea has a respectable precedent. In myasthenia gravis, antibodies attack the receptor at the junction between nerve and muscle, and the muscle stops answering the nerve. In 2000 the neuroimmunologists Steven Vernino and Vanda Lennon at the Mayo Clinic asked whether the same could happen at the ganglia. Those are the relay stations of the autonomic nervous system, where one nerve hands its signal to the next.

The chemical used at that handover is acetylcholine, and the structure that receives it is the ganglionic acetylcholine receptor. They built an assay and found antibodies to that receptor in autoimmune autonomic neuropathies. Levels tracked severity and fell when patients improved. That finding made autoimmune autonomic disease a real category. In the Mayo series of 152 POTS patients, the same antibody turned up in about 1 in 7.

Functional assays show antibodies changing what a vessel does

Two receptor names are needed for what follows. The alpha-1 receptor is the one the sympathetic nerves use to make a vessel squeeze. The beta-1 receptor is the one they use to speed the heart.

The stronger claim came from Oklahoma. The endocrinologist David Kem, with Hongliang Li, Xichun Yu and the immunologist Madeleine Cunningham, tested whether these patients carry antibodies that change how those receptors behave rather than merely sticking to them. They dripped patient serum onto living rat arterioles, the small vessels that do most of the squeezing, and reported an autoimmune basis for POTS in 2014. Blocking the alpha-1 receptor with a drug abolished the constricting effect.

Separately, the same serum behaved as a partial blocker, shifting the dose-response curve to the right so that more signal was needed for the same squeeze. In cells engineered to display beta-1 receptors, that serum switched them on. The proposed picture is compact.

An antibody that partly blunts the vessels forces the nervous system to shout louder, and a second antibody that stimulates the heart converts the shouting into tachycardia. The Swedish cardiologist Artur Fedorowski joined the group and reproduced the antiadrenergic pattern in an independent European cohort, using the same non-standard assays.

The commercial antibody test does not separate POTS patients from controls

In 2022 a team in Calgary and Malmo took serum from 116 patients and 81 healthy controls and tested it against 11 cardiovascular receptors, using the commercial assay that clinics can actually buy. The group included the cardiologists Juliette Hall, Viktor Hamrefors, Robert Sheldon and Satish Raj, with the neurologist Steven Vernino.

One of its authors had produced the Swedish replication and another had been on the original Oklahoma paper. Their detection study using standard methodology found no difference between the groups. Ninety-eight percent of patients and 100 percent of controls sat above the manufacturer's positive threshold for the alpha-1 antibody, which says more about the threshold than about the patients.

The null refutes the commercial test as a diagnostic. It does not refute the functional assays, which measure a different thing: what serum does to a living vessel rather than what sticks to a plate. Steven Vernino and Lauren Stiles state the position exactly in their review of autoimmunity in POTS.

The circumstantial case is strong, with post-infectious onset in a large fraction, overwhelming female predominance, and autoimmune conditions clustering in these families. The direct case is weak, with no antibody shown to cause the syndrome and no validated test.

A binding assay asks whether the antibody is there. It cannot ask what that antibody does in the particular circulation it meets, and the model expects that answer to differ from person to person. Which is how a presence test and a function test can disagree without either being wrong.

What the model adds is a reading of what a partial receptor blockade would even be. It is not a lesion. Nothing is destroyed and nothing is missing. The receptor still works and now needs more signal to produce the same squeeze, which means the loop still reaches its target by spending more. That is a change in what regulation costs, and the tachycardia is the cost showing up where somebody thought to count it.

Infection produces POTS at a rate the pandemic made visible

Thirty-one percent of 467 severely disabled long COVID patients at Karolinska met POTS criteria on formal testing, none of them having been hospitalized for the infection. Post-infectious onset in POTS is older than the pandemic by decades.

Ronald Schondorf reported it in 7 of his original patients in 1993, and the Mayo series put subacute onset at 14 percent of 152 cases in 2007. What changed after 2020 is the number of people it happened to at once.

Svetlana Blitshteyn, a neurologist in Buffalo, published a case series of POTS and other autonomic disorders after infection. She reviewed 20 patients who came to her between April and December 2020 with persistent neurological and cardiovascular complaints. Fifteen met criteria for POTS, 3 had neurally mediated fainting, and 2 had orthostatic hypotension. Six to 8 months later, 17 of the 20 still had autonomic symptoms.

A Karolinska cohort put a number on it

A team including the cardiologists Mikael Bjornson, Marcus Stahlberg and Artur Fedorowski, working with the infectious disease physician Judith Bruchfeld, followed 467 people who had never been hospitalized for COVID-19. All of them were still so unwell a year later that they were on at least half-time sick leave. Everyone with suspected orthostatic problems went to a cardiologist for 48-hour monitoring, tilt testing and an active stand test. One hundred and forty-three of them, 31 percent, met criteria in that 2025 prevalence study.

Ninety-one percent of them were women. They walked shorter distances in 6 minutes at higher heart rates and were less physically active than the rest. Their symptom profile could not be told apart from the other patients, which means symptoms alone cannot identify who has POTS. Only the standing measurements could.

The vaccination data, with its limits stated

The cardiologists Alan Kwan and Susan Cheng at Cedars-Sinai searched the records of 284,000 vaccinated people, comparing how often the diagnosis appeared in the 90 days after vaccination with the 90 days before. The odds were modestly higher afterwards, and higher than for the ordinary primary care diagnoses used as a reference.

They were about 5 times lower than the odds following SARS-CoV-2 infection itself, in their report of apparent POTS risks after vaccination and infection. This is a study of diagnostic codes rather than verified diagnoses. It detects association rather than cause.

Post-viral illness in general belongs to long COVID. An infection is an input. It arrives at a nervous system that already holds a set point, a reserve and a history, and what it leaves behind depends on all three.

That is why the same virus produces nothing in most people, a fortnight of fatigue in many, and a 2-year orthostatic illness in a few. The same virus passing through a different tone is a different biological event, and the system that meets it carries the outcome the virus does not.

Hypermobile joints and mast cells travel with POTS on unequal evidence

Fifty-five percent of 91 POTS patients had hypermobile connective tissue on formal assessment. A 2025 systematic review of the mast cell claim found no study that had tested it properly. The two associations are not in the same evidential position.

Connective tissue is the material that holds the body together: the collagen in skin, ligament, tendon and the walls of vessels. In hypermobile Ehlers-Danlos syndrome that material is more compliant than usual, so joints move further than they should.

A Penn State group applied the 2017 diagnostic checklist to 91 patients with postural tachycardia and reported the prevalence of hypermobile Ehlers-Danlos syndrome in POTS. The authors included the physiologist Amanda Miller, the clinical pharmacologist Amy Arnold, the clinical geneticist Clair Francomano and Lauren Stiles. Thirty-one percent met the full criteria. Another 24 percent had generalized joint hypermobility without meeting the full definition.

Why the two travel together is not established. The intuitive explanation, that more compliant veins stretch further under gravity and pool more blood, is a hypothesis rather than a finding. It is a hypothesis about constraint, the amount of give a tissue has. It is testable by measuring venous compliance in hypermobile and non-hypermobile patients who show the same heart rate rise.

The mast cell claim has never been tested to the standard it is repeated with

Mast cells are the immune cells that release histamine during an allergic reaction. The clinical pharmacologist Cyndya Shibao and the Vanderbilt group noticed that some patients flush, and measured a urinary marker of mast cell activation. They found a hyperadrenergic subgroup with mast cell activation who flushed, became breathless, and had headaches and gut symptoms, set off by standing, exercise, meals and the premenstrual week. On autonomic testing these patients showed a strongly hyperadrenergic pattern, with an exaggerated pressure overshoot after a forced exhalation.

Then the null, and it is recent. Allergists at the Mayo Clinic, led by Matthew Farley with Alexei Gonzalez-Estrada, went looking for the evidence behind the widely repeated claim that mast cell activation, hypermobility and postural tachycardia form a triad. They searched four databases, screened 200 records and read 92 full papers for a 2025 systematic review. Not one study met their prespecified criteria for diagnosing mast cell activation properly in patients with a confirmed diagnosis of either condition. One came close.

That is not a refutation. It is a statement that the claim has never been tested to a standard that would let anyone make it. The triad is clinically familiar and evidentially unproven, and both halves of that sentence carry weight. A model that reads POTS as a coupled failure has an obvious appetite for a connective tissue story and an immune story, which is exactly why it should be the last to overstate either.

In POTS the average brain blood flow is normal and its steadiness is not

Across four tilt angles, slow oscillations in brain blood velocity grew 61, 82, 161 and 264 percent in POTS patients while controls did not change at all. Mean velocity was normal at every angle, and working memory scores fell from 78 percent correct to 33 percent.

Patients describe their thinking failing when they stand. Julian Stewart and the physiologist Marvin Medow set out to measure that. Eleven patients and 9 controls performed a working-memory task while being tilted in stages to 15, 30, 45 and 60 degrees. Blood velocity in a brain artery was tracked continuously by ultrasound through the skull, in a 2015 study of oscillatory cerebral blood flow and impaired neurocognition.

Meanwhile the brain lost the ability to send extra blood to the tissue doing the work, which is how thinking is normally supplied. In controls, velocity rose about 4 percent above baseline while they worked at the task, and stayed there. In patients that rise fell away to almost nothing by 60 degrees. The size of the oscillation accounted for three-quarters of the variation in how well the extra blood arrived.

The mean was fine. The regulation of the mean was not, and the person could no longer think. Those two results belong together, because a normal average is what makes the unstable one easy to miss.

The forecast is already wrong 8 seconds before standing

The same laboratory then went earlier, into the seconds before standing, in 32 healthy volunteers and 54 patients. About 8 seconds before a person stands, the brain issues an anticipatory command that raises blood pressure ahead of the demand. In healthy people, and in patients who breathe normally on standing, brain blood velocity rises along with it.

In the patients who hyperventilate and blow off carbon dioxide, velocity falls instead, before they have moved, which Stewart and Medow reported in 2023 as anticipatory central command decreasing cerebral blood velocity. That fall went with a baroreflex that answered less. Nothing has happened to the body yet, and the forecast is already wrong.

The instrument is where the literature disagrees with itself

Ronald Schondorf, who had helped name the condition 12 years earlier, went looking for the cerebral blood flow abnormality everyone assumed was there, in 27 patients and 17 controls. He did not find it, and titled the 2005 paper a report that cerebral autoregulation is preserved in POTS. Autoregulation, measured by how faithfully brain velocity tracked pressure across a range of frequencies, was no different from healthy people and did not degrade as the tilt went on.

A Dutch cardiology group argued that velocity in one artery through the skull is too crude to answer the question. They used Doppler imaging of the neck arteries instead, measuring actual flow through a 30-minute tilt. Their 429 patients carried a diagnosis of chronic fatigue syndrome. Orthostatic intolerance is common in that illness and the two populations overlap heavily in these laboratories, which is why the cohort bears on POTS.

Flow at the end of tilt fell 7 percent in 44 healthy controls and 26 percent across the patients, in a study finding reduced cerebral blood flow even without hypotension or tachycardia. Among the patients whose heart rate and blood pressure responses were entirely normal it fell 24 percent, and 82 percent of that group crossed the abnormal threshold. Long COVID gives that study its full treatment.

Both results are real, and read through the model they tell one story from opposite ends. The number used to make the diagnosis and the physiological problem can come apart in either direction. Schondorf's patients met the criterion with intact autoregulation. In the Dutch cohort a person could lose nearly a quarter of the blood reaching the brain without ever crossing the 30-beat line. The criterion and the physiology are two different measurements.

POTS is one organization measured at five sites

Partly denervated legs. Reduced transporter protein. A kidney that will not defend its volume. Hearts 13 percent smaller. Stroke volume that collapses on standing. Brain flow whose average holds and whose steadiness fails. A forecast that is wrong 8 seconds before the movement. Medicine files those findings under different specialties. The Unified Model of Tone reads them as one thing.

Tone is the integrated organization of the body's interacting state transitions, taken as one bound state rather than a list of parts. In an upright body that means the way heart rate, vessel squeeze, blood volume, muscle pumping and the sensors reading all of them are related at a given instant.

Not their individual values. The relation between them. The rhythms measured above, the beat, the breath and the slow swing in brain flow, are the carrier that organization is written on. Tone is not any one of them.

Coupling: each part measures near normal and the standing answer still fails

Coupling is what the POTS criterion measures. Standing is answered by five systems arriving in phase, and in these patients each part measures close to normal on its own. Resting baroreflex function was intact in the Dallas cohort, the one with the smaller hearts. The arms responded normally to every challenge in the Vanderbilt leg-vein study.

Total noradrenaline output into the circulation was proportionate in the Melbourne microelectrode work. What is wrong sits between the parts. The legs do not squeeze, so the heart covers it with rate. The volume is low, so each beat carries less, so the rate rises again. That is coupling failing while every part still works.

The measurements that came back normal are the reason the one abnormal measurement exists. The pressure held. Something had to hold it.

Set point: the target is still met, at the highest available price

The diagnostic criterion says the pressure does not fall, and that clause is a statement about targets. The system has not lost its target. It has lost the cheap way of reaching it, and it is paying the difference every minute the person stays upright. A standing heart rate of 130 is what a set point looks like when it is being defended by the most expensive means available.

Input quality: the kidney and the brain both act on false reports

A kidney that will not release renin in a genuinely underfilled body is not a broken kidney. It is an organ acting correctly on a report that says the tank is full. A brain that lowers its own blood velocity 8 seconds before a person stands is acting correctly on a forecast that is wrong. Both are failures of input quality, and a regulator can only be as good as what it is told.

The baroreflex needs one clarification, because POTS research cites it on both sides. Cardiovagal gain on standard autonomic testing, the measure that was intact in the Dallas cohort, is how much the heart lengthens a beat for each unit of rise in pressure. Sensitivity measured under an orthostatic challenge is a different reading, taken while the loop is being asked to do the job it is failing at. The sympathetic arm behaves differently again.

Drop the pressure on purpose with a drug and these patients answer harder than controls, while the size of each burst never grows. That is a system spending more signal for the same effect rather than one with more reach. The model's claim is about the cardiovagal arm under challenge, and the claim is testable. Cardiovagal baroreflex sensitivity that comes back reduced under orthostatic challenge in patients who meet the tachycardia criterion confirms the input quality reading of POTS.

Switching the compensation off stops the tachycardia in seconds

The most direct evidence that the POTS heart rate is an answer rather than a disease is that it can be switched off from outside the heart. Schondorf's group, whose patients had intact autoregulation, inflated pressure trousers around their legs.

The tachycardia dropped substantially, autoregulation did not change, and symptoms improved in half of them. In the Mayo suction chamber, blocking the pooling collapsed a 39-beat rise to 9. Stop the blood from pooling and the racing heart stops within seconds, without anything being done to the heart.

The heart rate is the answer to a question the body is being asked. Change the question and the answer changes, which is why the number is a poor description of the illness and an excellent description of what the illness costs.

A system that can be read at five sites can also be entered at more than one. A cuff inflated around a leg is not a cardiac intervention by any ordinary description. It enters the loop at the structural boundary, changing what the vessels are asked to hold, and the rate answers. Because the loop is continuous, an input introduced at any point in it travels through the rest. Where an input is delivered therefore says little about what it reaches.

Health is the range, and POTS is that range collapsed onto one solution

Health is not relaxation and it is not a low heart rate. Tone within its healthy range keeps the flexibility to adapt, so a well-regulated body can be flat, upright, sprinting or asleep, and can move between those states without paying much for any of them.

Tone that drifts or distorts outside that range is what manifests as illness, and in POTS the distortion is a range collapsing onto one solution used constantly. These patients have not lost the ability to hold blood pressure. They have lost every way of holding it except one.

POTS symptoms improve only when the lower standing heart rate comes with more capacity

A low dose of propranolol slowed the standing heart rate and improved symptoms in 54 patients. A high dose slowed the heart considerably further and delivered less relief. The benefit does not scale with the blockade, and that is the most informative failure in the POTS drug literature.

Rate control is the most-studied drug approach in POTS, and propranolol is the most-studied drug within it. It is a beta blocker, meaning it occupies the receptors the sympathetic nerves use to speed the heart, so less of that signal reaches the heart. If the racing heart were the disease, more blockade should mean more relief.

A Vanderbilt trial ran two comparisons and published them under the title less is more. Against placebo in 54 patients, a low dose slowed the standing heart rate and improved the symptom burden. In a second, smaller comparison of two doses in 18 patients, the high dose slowed the heart considerably further and delivered less symptom relief than the low dose had. The lower heart rate came with more symptoms, not fewer.

Enough blockade to let the heart fill produced a fitter patient

Amy Arnold's group tested capacity rather than symptoms. Eleven patients and 7 healthy people cycled to exhaustion an hour after either placebo or a single low dose. Maximum oxygen uptake rose about 13 percent in the patients and did not move in the healthy people, in a randomized study of low-dose propranolol and exercise capacity.

The paper reports that rise alongside two other changes: a peak heart rate blunted from 165 to 142, and a stroke volume that climbed from 67 to 81 milliliters. A separate group was given either a high dose of the same drug or a dose of metoprolol, which blocks the same receptors more narrowly at the heart. Both lowered heart rate just as much and did nothing for exercise capacity.

That pair of results is the central POTS distinction, written in numbers. Enough blockade to let the heart fill produced a fitter person. More blockade produced a slower heart and nothing else. The benefit had a window, which is what the model expects of any input. Too little is not registered, a matched amount is integrated, and too much becomes something the system has to defend against.

What the POTS exercise literature shows

Qi Fu and Benjamin Levine designed a training program that begins horizontal, on a recumbent bicycle, a rowing machine or in water, precisely because upright posture is what provokes symptoms. It moves toward upright only as capacity returns, an approach they set out in a 2018 review of non-pharmacological treatment.

In their laboratory study 19 patients completed 3 months. Left ventricular mass rose about 12 percent, blood volume about 7 percent, and standing heart rate fell 9 beats. Ten of the 19 no longer met criteria. There was no untrained control arm, so expectation and the ordinary tendency of extreme measurements to drift back toward average cannot be excluded.

An international registry led by the physician Stephen George with Qi Fu and Benjamin Levine took the same 3-month program, paired with strength work and increased salt and fluid intake, out to patients' own doctors. Two hundred and fifty-one enrolled and 103 finished that community-setting trial.

Of those who finished, 71 percent no longer met criteria, and the standing rise fell from 46 beats to 23. The attrition is part of the finding. Fewer than half completed, and only completers were counted. The best-supported approach in POTS is also the hardest thing to ask of a person who cannot stand up.

The drug evidence, stated as the field states it

An Adelaide group led by the researcher Rachel Wells with the cardiologist Dennis Lau searched more than 2,000 records for a systematic review of POTS therapies. They could include 28 studies: 25 uncontrolled case series covering 755 patients, and 3 small randomized trials covering 103. Response rates ran between 51 and 72 percent across volume expansion, vessel tightening, rate control and exercise, with almost no head-to-head comparison anywhere. Their own word for the evidence base is extremely limited. No medication is approved specifically for POTS.

Other approaches aim elsewhere. Pyridostigmine blocks the enzyme that destroys acetylcholine, the transmitter the vagus nerve uses, so the braking signal lasts longer at the heart. In a Vanderbilt crossover, acetylcholinesterase inhibition improved the tachycardia and symptoms without blood pressure dropping.

The cardiologists Pam Taub and Jonathan Hsu in San Diego tested ivabradine in hyperadrenergic POTS, a drug that slows the pacemaker current inside the sinus node itself without touching the sympathetic receptors at all. Twenty-two patients selected for a hyperadrenergic pattern completed the crossover. Heart rate fell and physical functioning improved, with nobody left with a dangerously slow heart or a dropped pressure.

Groups in Calgary and Nashville, with Jaiden Uppal as first author, then ran the head-to-head comparison. Twenty-eight women took 4 weeks each of ivabradine, propranolol and placebo in random order, published in 2026. On tilt testing the standing rise was 33 beats on placebo, 24 on ivabradine and 25 on propranolol.

Both drugs pushed the rise below the 30-beat line that defines the illness, and neither beat the other. The investigators describe the symptom and quality-of-life gains as selective rather than uniform, and patient preference split between the two drugs. Two different mechanisms, the same number, and no agreement about which one people wanted to keep taking.

The same fall in heart rate meant two different states of the person

Nineteen patients took propranolol or placebo double-blind for 4 weeks, then all of them trained for 3 months, in a Dallas trial of exercise training versus propranolol. The kidney's aldosterone response to renin, the reporting failure described earlier, did not shift at all on the drug and rose modestly after training. Standing cardiac output fell on the drug, so the body was moving less blood, and barely changed with training.

Both lowered standing heart rate, which is the number everyone watches. Quality of life improved after training, on physical and social functioning both, and did not move on the drug. The same fall in heart rate meant two entirely different things about the state of the person, and no chart records which one happened.

Two very different inputs sit inside that comparison, and they reached the same number by different routes. A program that begins horizontal and works toward upright enters this organization through posture and mechanical load. A molecule enters it through receptor coupling. Those are two entrances to one regulated system, and the model ranks neither above the other. The line that matters runs across the entrances rather than between them, and it sorts inputs by what they are aiming at.

That is the distinction the model draws between restoring a regulator and managing its output, and it is drawn without contempt for either. Both are legitimate achievements. A person who cannot stay upright long enough to work needs the output managed now, and relief has real value on its own terms.

Nobody should read a paragraph on a website as a reason to start, stop or change anything they are taking. The point is about measurement. A falling heart rate is compatible with a person getting better and with a person getting worse, so the number cannot be the thing that is watched.

The experiment that would settle the tone reading of POTS has not been run

Nothing in the POTS literature stratifies patients by a tone measure recorded before treatment and then shows them converging on the middle from both directions against a matched sham. The instruments to build that study already exist.

The model's sharpest claim is easy to state and hard to satisfy. A drug is directional by construction. It lowers a value in everyone who responds, including people in whom that value was already low, because it acts on one mechanism in one direction.

A genuine restoration of a regulator is not directional. It moves a dysregulated value toward the middle of its healthy range from whichever side the person started on. What has been corrected is the ability to find the middle rather than the height of the number.

Two results would mark an input as a mask instead. A uniform shift, both groups moving the same direction regardless of where they began, helps whichever group it points at and carries the other further from the middle. Convergence no greater than the sham arm produces says the same thing. The study is buildable with instruments that exist, and it has not been built.

Baroreflex sensitivity before treatment predicts who responds

The nearest approach is a weaker and genuinely interesting prediction. Baroreflex sensitivity measures how well the loop works: how many milliseconds the heart lengthens its beat for each millimeter of mercury the pressure rises. Pediatricians at Peking University First Hospital in Beijing studied 54 children treated with metoprolol and reported that baroreflex sensitivity predicts the therapeutic effect. Yaxi Cui was first author, with Junbao Du and Hongfang Jin as senior authors. They split the children into responders, whose symptom score at least halved, and non-responders.

Age, sex, body size, illness duration, dose and follow-up time were the same in both groups. What differed was a measurement taken before treatment began. Above a supine baroreflex sensitivity of roughly 8 milliseconds per millimeter of mercury the children responded, and below it most did not.

That single pre-treatment reading picked out about 3 responders in 4 and correctly cleared nearly every non-responder. The cut-off was derived in the same sample it was tested in, so it needs independent validation before anyone leans on it.

The neurologists Bridget Mueller and Jessica Robinson-Papp in New York found the same measure doing double duty. They studied 34 patients attending a headache clinic, 11 of whom had POTS, and found that reduced cardiovagal baroreflex sensitivity is associated with POTS and with pain chronification.

The same measure independently predicted the tipping of episodic headache into chronic headache, meaning more than 15 headache days in a month. One regulator, two apparently unrelated diagnoses, in the same people. The sample is small and the confidence intervals are wide, so the finding needs repeating before it carries much weight.

What would confirm this reading of POTS

First, lowering the heart rate does not by itself restore function, and that gap between rate and function confirms that the tachycardia is a sign rather than the disease. The evidence cuts both ways and both halves belong here. In the 2026 crossover trial two different rate-lowering drugs did improve symptoms against placebo, and that is a real counterweight.

Against it sit the propranolol dose studies, where more blockade lowered the rate further and gave less relief, and the training comparison, where the same fall in rate produced two different people. The test stays available. A large trial in which function recovers out of proportion to the rate reduction settles the matter for this reading.

Second, tone is claimed to be one variable rather than several. Baroreflex sensitivity, heart rate variability structure, blood volume regulation and recovery time load on one common factor in the same patients, and that shared factor confirms the claim. It is what makes the POTS reading above a single account rather than an assembly of coincidences. Heart rate variability is the most accessible of those measures and the obvious place to start.

What a restored system would look like is specific enough to check. The standing rise falls while stroke volume rises, rather than falling while the accelerator is held shut. Baroreflex sensitivity under challenge climbs toward the middle without overshooting it.

Oscillations in brain blood flow settle while the average stays where it was, and the cognitive score comes back with them. Symptoms move in step with the measurements instead of independently of them. None of that requires a technology that does not exist. It requires sorting patients by regulation before treating them, which is a study design rather than a discovery.

What is already settled matters more to the person reading this. POTS is real and has been measured in laboratories on three continents. The racing heart is its most visible feature rather than its most important one. The normal test results were never evidence against the illness. They were evidence about where it lives, and it lives in the regulation, which is the one part of a body that was always built to change.

How POTS relates to the rest of the library

POTS is a condition, and the foundations of tone are the properties it distorts. Each neighboring page carries one part of the POTS picture in full.

• Coupling is the page for what the 30-beat criterion actually measures: five systems that must arrive in phase, each of them near normal alone.
• Set point is where the defended value is taught, and POTS is the clearest case in the library of a target still being met at the highest available price.
• Input quality explains a kidney that will not release renin in an underfilled body and a brain whose forecast is wrong before the movement starts.

• Gain is the axis on which POTS patients answer a falling pressure with far more traffic than controls while burst size stays flat.
• Oscillation is where the slow swings in brain blood flow belong, the ones that grew 264 percent on tilt while the average held.
• Prediction covers the anticipatory command that drops brain velocity 8 seconds before standing.
• Load is the accumulated cost of holding pressure by rate alone, measured here in lost income and a 2-year diagnostic delay.
• Constraint is where hypermobile connective tissue and venous compliance are taught, the untested mechanism behind the strongest POTS association.
• Time course is the axis the deconditioning argument lives on, because a body that stopped moving after the illness and a body that became ill after it stopped moving look identical in a snapshot.

Four condition pages sit next to POTS.

• Dysautonomia is the broader case where regulation genuinely collapses instead of holding at a cost, and it carries the full anatomy of the baroreflex.
• Long COVID is where the post-infectious route into POTS is taught, along with the volume hormones and the neck-artery flow data.
• Heart rate variability is the instrument most likely to test whether these POTS measures move together.
• The autonomic nervous system is the anatomy every measurement on this page samples.

Frequently asked